Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 9, 2015, Pages 889-900

  Kahlert, Ulf D ^a,d   Suwala, Abigail K ^d   Koch, Katharina ^d   Natsumeda, Manabu ^a   Orr, Brent A ^c   Hayashi, Masanori ^b   Maciaczyk, Jarek ^d   Eberhart, Charles G ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d Institute of Pathology   (Germany)

Author keywords

AXIN2; CD133; Glioma; LGK974; Wnt; Catenin

Indexed keywords

ANTINEOPLASTIC AGENT; AXIS INHIBITOR PROTEIN 2; BETA CATENIN; CD133 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; LGK 974; LUCIFERASE; MESSENGER RNA; PROTEIN; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; WNT PROTEIN; LGK974; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATYPICAL TERATOID RHABDOID TUMOR; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEDULLOBLASTOMA; PONTINE GLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; UPREGULATION; WNT SIGNALING PATHWAY; BRAIN TUMOR; DRUG EFFECTS; DRUG SCREENING; GENETICS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ADULT; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHILD; GLIOBLASTOMA; HUMANS; PYRAZINES; PYRIDINES; TUMOR STEM CELL ASSAY; WNT SIGNALING PATHWAY;

EID: 84940529839     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000227     Document Type: Article

References (91)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
2. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401
3. Binda E, Reynolds BA, Vescovi AL. Glioma stem cells: Turpis omen in nomen? (The evil in the name?). J Intern Med 2014;276:25-40
4. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-21
5. Zheng H, Ying H, Yan H, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008;455: 1129-33
6. Lagadec C, Vlashi E, Frohnen P, Alhiyari Y, Chan M, Pajonk F. The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancerY and glioma-initiating cells. Stem Cells 2014;32:135-44
7. Jin X, Jin X, Jung JE, Beck S, Kim H. Cell surface nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun 2013;433: 496-501
8. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I, Ruiz i Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J 2010; 29:2659-74
9. Gangemi RMR, Griffero F, Marubbi D, et al. SOX2 silencing in glioblastoma tumorYinitiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009;27:40-48
10. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60
11. Schonberg DL, Lubelski D, Miller TE, Rich JN. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med 2014;39:82-101
12. Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother 2015:1-12
13. Rampazzo E, Persano L, Pistollato F, et al. Wnt activation promotes neuronal differentiation of glioblastoma. Cell Death Dis 2013;4:e500
14. Yang W, Xia Y, Ji H, et al. Nuclear PKM2 regulates A-catenin transactivation upon EGFR activation. Nature 2011;480:118-22
15. Zheng H, Ying H, Wiedemeyer R, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 2010;17:497-509
16. Gong A, Huang S. FoxM1 and Wnt/A-catenin signaling in glioma stem cells. Cancer Res 2012;72:5658-62
17. Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(Ylike) transition as a relevant molecular event in malignant gliomas. Cancer Lett 2013;331:131-38
18. MacDonald BT, Tamai K, He X. Wnt/A-catenin signaling: Components, mechanisms, and diseases. Dev Cell 2009;17:9-26
19. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80
20. Ring A, Kim Y-M, Kahn M. Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev 2014;10:512-25
21. Sonderegger S, Pollheimer J, Knöfler M. Wnt signalling in implantation, decidualisation and placental differentiationVreview. Placenta 2010;31: 839-47
22. Miki T, Yasuda S, Kahn M. Wnt/A-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev 2011;7: 836-46
23. Nusse R. Wnt signaling and stem cell control. Cell Res 2008;18:523-27
24. Pinto D, Gregorieff A, Begthel H, Clevers H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev 2003; 17:1709-13
25. Kalani MYS, Cheshier SH, Cord BJ, et al. Wnt-mediated self-renewal of neural stem/progenitor cells. Proc Natl Acad Sci U S A 2008;105: 16970-75
26. Zechner D, Fujita Y, Hülsken J, et al. Beta-catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol 2003;258:406-18
27. Wexler EM, Paucer A, Kornblum HI, Palmer TD, Geschwind DH. Endogenous Wnt signaling maintains neural progenitor cell potency. Stem Cells 2009;27:1130-41
28. Mikels AJ, Nusse R. Wnts as ligands: Processing, secretion and reception. Oncogene 2006;25:7461-68
29. Buechling T, Boutros M. Wnt signaling at and above the receptor level. Curr Top Dev Biol 2011;97:21-53
30. Gao C, Chen YG. Dishevelled: The hub of Wnt signaling. Cell Signal 2010;22:717-27
31. Pu P, Zhang Z, Kang C, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 2009;16:351-61
32. Jiang X, Yu Y, Yang HW, Agar NY, Frado L, Johnson MD. The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth. J Biol Chem 2010;285:8472-80
33. Guo M, Zhang X, Wang G, et al. miR-603 promotes glioma cell growth via Wnt/A-catenin pathway by inhibiting WIF1 and CTNNBIP1. Cancer Lett 2015;360:76-86
34. Kahlert UD, Maciaczyk D, Doostkam S, et al. Activation of canonical WNT/A-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett 2012;325:42-53
35. Tu Y, Gao X, Li G, et al. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res 2013;73:6046-55
36. Vassallo I, Zinn P, Lai M, Rajakannu P, Hamou MF, Hegi ME. WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. Oncogene 2015. doi: 10.1038/onc.2015.61 [Epub ahead of print]
37. Kim Y, Kim KH, Lee J, et al. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 2012;92:466-73
38. Kaur N, Chettiar S, Rathod S, et al. Wnt3a mediated activation of Wnt/A-catenin signaling promotes tumor progression in glioblastoma. Mol Cell Neurosci 2013;54:44-57
39. Jho E, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002;22: 1172-83
40. Leung JY, Kolligs FT, Wu R, et al. Activation of AXIN2 expression by beta-cateninYT cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem 2002;277:21657-65
41. Chia IV, Costantini F. Mouse axin and axin2/conductin proteins are functionally equivalent in vivo. Mol Cell Biol 2005;25:4371-76
42. Lambiv WL, Vassallo I, Delorenzi M, et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro-oncology 2011;13:736-47
43. Zhang W, Shen C, Li C, et al. miR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway. Mol Carcinog 2015. doi: 10.1002/mc.22304 [Epub ahead of print]
44. Zhang N, Wei P, Gong A, et al. FoxM1 promotes A-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011;20:427-42
45. Götze S, Wolter M, Reifenberger G, Müller O, Sievers S. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer 2010;126:2584-93
46. Augustin I, Goidts V, Bongers A, et al. The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol Med 2012;4: 38-51
47. Kamino M, Kishida M, Kibe T, et al. Wnt-5a signaling is correlated with infiltrative activity in human glioma by inducing cellular migration and MMP-2. Cancer Sci 2011;102:540-48
48. Yu JM, Jun ES, Jung JS, et al. Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett 2007;257:172-81
49. Jin X, Jeon H-Y, Joo KM, et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res 2011;71:3066-75
50. Zheng Y, McFarland BC, Drygin D, et al. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. Clin Cancer Res 2013;19:6484-94
51. Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A 2013;110: 20224-29
52. Jiang X, Hao H-X, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2013;110:12649-54
53. Tzeng H-E, Yang L, Chen K, et al. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: Resistance reversal with WNT inhibitor. Oncotarget 2015;6: 11061-73
54. Kahlert UD, Bender NO, Maciaczyk D, et al. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cellYrelated gene expression profile in in vitro propagated glioblastoma multiformeYderived cell line with a PNET-like component. Folia Neuropathol 2012;50:357-68
55. Heaphy CM, Schreck KC, Raabe E, et al. A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathol 2013; 126:607-8
56. Ahsan S, Raabe EH, HaffnerMC, et al. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathol Commun 2014;2:59
57. Fuerer C, Nusse R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS One 2010;5:e9370
58. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72:8463-71
59. Kahlert UD, Suwala AK, Raabe EH, et al. ZEB1 promotes invasion in human fetal neural stem cells and hypoxic glioma neurospheres. Brain Pathol 2014. doi: 10.1111/bpa.12240 [Epub ahead of print]
60. Mao X, Hütt-Cabezas M, Orr BA, et al. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget 2013;4: 1050-64
61. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1
62. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000;59: 333-37
63. Fattet S, Haberler C, Legoix P, et al. Beta-catenin status in paediatric medulloblastomas: Correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009;218:86-94
64. Schreck KC, Taylor P, Marchionni L, et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: A potential mechanism of therapeutic resistance. Clin Cancer Res 2010;16:6060-70
65. Sareddy GR, Kesanakurti D, Kirti PB, Babu PP. Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/A-catenin/Tcf signaling pathway in human glioblastoma cells. Neurochem Res 2013;38:2313-22
66. Taylor KR, Mackay A, Truffaux N, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 2014;46:457-61
67. Graham C, Tucker C, Creech J, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006;12:223-34
68. Brandt WD, Schreck KC, Bar EE, et al. Notch signaling activation in pediatric low-grade astrocytoma. J Neuropathol Exp Neurol 2015;74: 121-31
69. Trent J, Meltzer P, Rosenblum M, et al. Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma. Proc Natl Acad Sci U S A 1986;83:470-73
70. Bai R, Siu I-M, Tyler BM, Staedtke V, Gallia GL, Riggins GJ. Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. Neuro-oncology 2010;12:655-63
71. Piccirillo SGM, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumourYinitiating cells. Nature 2006;444:761-65
72. Liu H, Liu Z, Jiang B, Peng R, Ma Z, Lu J. SOX9 overexpression promotes glioma metastasis via Wnt/A-catenin signaling. Cell Biochem Biophys 2015. doi: 10.1007/s12013-015-0647-z [Epub ahead or print]
73. Zhang K, Zhu S, Liu Y, et al. ICAT inhibits glioblastoma cell proliferation by suppressing Wnt/A-catenin activity. Cancer Lett 2015;357:404-11
74. Yan Z, Wang J, WangC, JiaoY, QiW, Che S.miR-96/HBP1/Wnt/A-catenin regulatory circuitry promotes glioma growth. FEBS Lett 2014;588:3038-46
75. Rattner A, Hsieh JC, Smallwood PM, et al. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci U S A 1997;94:2859-63
76. Roth W, Wild-Bode C, Platten M, et al. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 2000;19:4210-20
77. Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003;423:448-52
78. Paraf F, Jothy S, Van Meir EG. Brain tumorYpolyposis syndrome: Two genetic diseases? J Clin Oncol 1997;15:2744-58
79. Liu C, Tu Y, Sun X, et al. Wnt/beta-catenin pathway in human glioma: Expression pattern and clinical/prognostic correlations. Clin Exp Med 2010;11:105-12
80. Yang C, Iyer RR, Yu ACH, et al. A-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc Natl Acad Sci U S A 2012;109:6963-68
81. Shi Z, Qian X, Li L, et al. Nuclear translocation of A-catenin is essential for glioma cell survival. J Neuroimmune Pharmacol 2012;7:892-903
82. Zhang L-Y, Jiang L-N, Li F-F, et al. Reduced beta-catenin expression is associated with good prognosis in astrocytoma. Pathol Oncol Res 2010; 16:253-57
83. Zhang K, Zhang J, Han L, Pu P, Kang C. Wnt/beta-catenin signaling in glioma. J Neuroimmune Pharmacol 2012;7:740-49
84. Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des 2013;19:634-64
85. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010;1:563-77
86. De Robertis A, Valensin S, Rossi M, et al. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells. Mol Cancer Ther 2013;12:1180-89
87. Lan F, Yue X, Han L, et al. Antitumor effect of aspirin in glioblastoma cells by modulation of A-catenin/T-cell factorYmediated transcriptional activity. J Neurosurg 2011;115:780-88
88. Peng H, Jiang B, Zhao J, Chen B, Wang P. Risperidone promotes differentiation of glioma stem-like cells through the Wnt signaling pathway. Tumour Biol 2015. doi: 10.1007/s13277-015-3087-x [Epub ahead of print]
89. Rathod SS, Rani SB, Khan M, Muzumdar D, Shiras A. Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways. FEBS Open Bio 2014;4:485-95
90. Li Q, Shen K, Zhao Y, Ma C, Liu J, Ma J. MiR-92b inhibitor promoted glioma cell apoptosis via targeting DKK3 and blocking the Wnt/A-catenin signaling pathway. J Transl Med 2013;11:302
91. Delic S, Lottmann N, Stelzl A, et al. MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation. Neuro-oncology 2014;16:179-90